$24.98 $0.83 per serving
Product analysis
SAMe 400 mg may support joint comfort, though the benefit is uncertain and its named form does not establish the same absorption as the preparations behind that benefit.
AI assessment of the formula, label and price. How scoring works
Nutrient Quality40
The SAMe form is identified, but its stability and absorption cannot be judged confidently. Naming the salt does not establish equivalence to other preparations.
Ingredient Transparency100
The SAMe amount and form are both disclosed. That makes the ingredient easier to compare with other SAMe supplements.
Value For Money80
The serving offers favorable value for the amount of active SAMe. The price advantage does not establish equivalent absorption or results.
Customer Satisfaction81
Customer feedback is favorable across a substantial review pool. Those opinions describe satisfaction rather than establishing joint or mood benefits.
Product Focus71
The single ingredient keeps the formula simple despite several intended uses. Joint and mood benefits remain conditional, while routine stress relief and toxin clearance are not established.
- Format
Tablet - Container
- 30 Tablet(s)
- Per serving
- $0.83
- Also available
SAMe 400 mg$40.20- Customer rating
- 4.7 · 1,124 ratings
Goals
Impact
Moderate effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
Impact
Highest effect
SAMe · 400 mg
Impact
High effect
SAMe · 400 mg
SAMe Not classified
No linked studies yet.
Ingredients
| Ingredient | Amount per serving | Score |
|---|---|---|
SAMe (S-Adenosyl-L-Methionine Disulfate Tosylate) | 400 mg |
SAMe (S-Adenosyl-L-Methionine Disulfate Tosylate) · 400 mg OverallScore76
The serving provides 400 mg of SAMe at a moderate cost per 400 mg. Blister packaging is not documented. The active yield is not clearly separated from the salt weight.
How this ingredient is rated
Active Ingredient Quality & Bioavailability77
A stabilized SAMe salt is indicated, but its specific form is unclear. Protective blister packaging is not documented, so moisture protection is unclear.
Stabilized Salt Form
A stabilized SAMe salt is indicated, but its specific form is unclear.
Packaging Integrity
Protective blister packaging is not documented, so moisture protection is unclear.
Dose, Safety & Label Transparency72
A serving lists 400 mg of SAMe. The amount is not clearly distinguished as active SAMe versus salt weight.
Active Dosage Strength
A serving lists 400 mg of SAMe.
Net SAMe Yield Transparency
The amount is not clearly distinguished as active SAMe versus salt weight.
Value80
The cost per 400 mg of SAMe is moderate.
Price Per 400mg Active Dose
The cost per 400 mg of SAMe is moderate.
Alternative products
Report alternatives
Sources
Published studies used for the product analysis and the top-ranked studies for each ingredient and goal.
- S-adenosyl methionine (SAMe) versus celecoxib for the treatment of osteoarthritis symptoms: a double-blind cross-over trial. [ISRCTN36233495].
- Italian double-blind multicenter study comparing S-adenosylmethionine, naproxen, and placebo in the treatment of degenerative joint disease.
- Double-blind multicentre study of the activity of S-adenosylmethionine in hip and knee osteoarthritis.
- A long-term (two years) clinical trial with S-adenosylmethionine for the treatment of osteoarthritis.
- Exploring the mechanisms behind S-adenosylmethionine (SAMe) in the treatment of osteoarthritis.
- Early treatment efficacy of S-adenosylmethionine in patients with intrahepatic cholestasis: A systematic review.
- Ursodeoxycholic acid and S-adenosylmethionine in the treatment of intrahepatic cholestasis of pregnancy: a multi-centered randomized controlled trial.
- S-adenosyl-L-methionine for the treatment of chronic liver disease: a systematic review and meta-analysis.
- Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection.
- S-adenosylmethionine in alcoholic liver cirrhosis: a randomized, placebo-controlled, double-blind, multicenter clinical trial.
- Efficacy and tolerability of oral and intramuscular S-adenosyl-L-methionine 1,4-butanedisulfonate (SAMe) in the treatment of major depression: comparison with imipramine in 2 multicenter studies.
- A double-blind, randomized parallel-group, efficacy and safety study of intramuscular S-adenosyl-L-methionine 1,4-butanedisulphonate (SAMe) versus imipramine in patients with major depressive disorder.
- Preliminary results of a randomized controlled trial carried out with a fixed combination of S-adenosyl-L-methionine and betaine versus amitriptyline in patients with mild depression.
- S-adenosylmethionine blood levels in major depression: changes with drug treatment.
- Adjunctive Nutraceuticals for Depression: A Systematic Review and Meta-Analyses.